<DOC>
	<DOC>NCT00441337</DOC>
	<brief_summary>To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer</brief_summary>
	<brief_title>A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies</brief_title>
	<detailed_description>Six patients enrolled at each dose level of 0.3, 1.0, 3.0 and 10mg/kg; the remaining 10 to 15 patients may subsequently be enrolled at a dose at or below the maximum tolerated dose (MTD) during the dose-escalation portion of the study. Patients who respond may receive additional doses of drug.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Relapsed/refractory nonsmall cell lung cancer, colorectal adenocarcinoma, malignant melanoma, renal (clear) cell carcinoma, or hormonerefractory prostate adenocarcinoma Prior treatment must have been completed at least 4 weeks prior to enrollment No untreated primary or metastatic brain or meningeal tumors ECOG PS 0 or 1 Meet all screening laboratory values History of severe hypersensitivity reactions to other monoclonal antibodies Active autoimmune disease or a documented history of autoimmune disease Prior therapy with an antiPD1 or antiCTLA4 antibody Active infection Concurrent medical condition requiring the use of immunosuppressive medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>malignancies</keyword>
	<keyword>cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>malignant melanoma</keyword>
	<keyword>renal cancer</keyword>
	<keyword>renal carcinoma</keyword>
	<keyword>carcinoma</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate adenocarcinoma</keyword>
	<keyword>Recurrent or treatment refractory malignancies</keyword>
</DOC>